RECEIVED
CENTRAL FAX CENTER
APR 17 2008

In the Claims:

Claims 1 to **13** (cancelled).

Claim 14 (currently amended) A compound of the formula (I')



(I')

wherein

A is



R_{18}, R_{19} and R_{20} are independently selected from the group consisting of hydrogen, -OH, alkyl or alkoxy of 1 to 6 carbon atoms, R_{21} and R_{22} are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or R_{21} and R_{22} form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently selected from the group consisting of O, N or

furthermore R_{21} is selected from the group consisting of alkylsulfonyl, alkylsulfoxide and alkylcarbonyl and then R_{22} is hydrogen,

B is thiophenyl,

X is selected from the group consisting of a bond or $-CO-NR_{36}-$,

Y is selected from the group consisting of a bond, and $-(CH_2)_n-$, $-(CH_2)_r-Q-(CH_2)_s-$ ~~and thiazolidine~~,

Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine, thiazolidine and a saturated carbon ring having 3 to 7 members,

Φ is $-(CH_2)_p-NR_{37}-(CH_2)_q-$,

R_{36} and R_{37} are independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and $-CO-R_{38}$, R_{38} is alkyl or alkoxy of 1 to 6 carbon atoms,

R_{39} is hydrogen,

m, n, p, q, r and s are independently integers from 0 to 6,

~~and~~ or its pharmaceutically acceptable salts.

Claims 15 to 19 (cancelled).

Claim 20 (previously presented) A compound of claim 14 selected from the group consisting of

- 2-amino-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-5-methoxybenzamide;

- 5-amino-N-(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-2-hydroxybenzamide;

- 4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-{4-[(methylsulphonyl)amino]phenyl}butanamide;

- 4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-[4-(dimethylamino)phenyl]butanamide;

- 5-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-[4-(dimethylamino)phenyl]pentanamide;

- (*4R*)-2-(3-{[amino(2-thienyl)methylidene]amino}-phenyl)-N-[4-(dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide;

- *tert*-butyl 3-{[amino(2-thienyl)methylidene]amino}benzyl{3-[4-(dimethylamino)anilino]-3-oxopropyl}carbamate;

- 3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]propanamide;

- 3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-[4-(4-morpholinyl)phenyl]propanamide;

- N'-[4-(2-{[5-(dimethylamino)-2-hydroxybenzyl]amino}ethyl)phenyl]-2-thiophenecarboximidamide;

- N-(4-{[(4-{[amino(2-thienyl)methylidene]amino}phenethyl)-amino]methyl}phenyl)acetamide;

- N'-[4-(2-{[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino}-ethyl)phenyl]-2-thiophenecarboximidamide;

- N'-{4-[2-({[4-(dimethylamino)anilino]carbonyl}amino)-ethyl]phenyl}-2-thiophenecarboximidamide;

- N'-(4-{2-[[5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methyl)amino]ethyl}phenyl)-2-thiophenecarboximidamide;

and or the pharmaceutically acceptable salts of the latter.

Claim 21 (withdrawn) A method of inhibiting NO synthase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

Claim 22 (withdrawn) A method of inhibiting lipidic peroxidation in a patient in need thereof comprising administrating to said patient a therapeutically effective amount of a compound of claim 14.

Claim 23 (cancelled).

Cancel **Claims 24** and **25**.